Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

174

Participants

Timeline

Start Date

September 15, 2021

Primary Completion Date

December 1, 2028

Study Completion Date

December 1, 2028

Conditions
Lymphoma, B-Cell
Interventions
DRUG

CC-220

CC-220 by mouth at the assigned dose starting on Day 1 for 14 consecutive days of the 21-day treatment cycle for 6 cycles of treatment.

DRUG

Rituximab

Rituximab 375 mg/m2 on Day 1 by intravenous (IV) infusion or 1400 mg (SC) subcutaneous (from Cycle 2) of a 21-day treatment cycle for up to a total of 6 cycles

DRUG

Cyclophosphamide

Cyclophosphamide 750mg/m2 on Day 1 by IV infusion of a 21-day treatment cycle for up to a total of 6 cycles

DRUG

Doxorubicin

Doxorubicin 50 mg/m2 IV infusion on Day 1 of a 21-day treatment cycle for up to a total of 6 cycles

DRUG

Vincristine

Vincristine 1.4 mg/m2 (maximum of 2.0 mg total) IV intravenous on Day 1 of a 21-day treatment cycle for up to a total of 6 cycles

DRUG

Prednisone

Prednisone 100 mg PO on Days 1 through 5 of each 21-day treatment or 100mg IV on Day 1 is also acceptable for up to a total of 6 cycles

DRUG

CC-99282

CC-99282 by mouth at the assigned dose starting on Day 1 for 7 consecutive days of the 21-day treatment cycle for 6 cycles of treatment.

DRUG

Polatuzumab vedotin

Polatuzumab vedotin 1.8 mg/kg on Day 1 by intravenous (IV) infusion of a 21-day treatment cycle for up to a total of 6 cycles

DRUG

Rituximab

Rituximab 375 mg/m2 on Day 1 by intravenous (IV) infusion of a 21-day treatment cycle for up to a total of 6 cycles

Trial Locations (34)

407

RECRUITING

Taichung Veterans General Hospital, Taichung

3080

COMPLETED

Local Institution - 301, Seoul

5000

COMPLETED

Local Institution - 501, Adelaide

10676

RECRUITING

Evangelismos General Hospital of Athens, Athens

12464

RECRUITING

Attikon University General Hospital, Athens

14263

WITHDRAWN

Roswell Park Cancer Institute, Buffalo

26500

WITHDRAWN

Local Institution - 703, Pátrai

28028

WITHDRAWN

Local Institution - 204, Madrid

29010

RECRUITING

H. Virgen de la Victoria, Málaga

32224

WITHDRAWN

Mayo Clinic - Jacksonville, Jacksonville

RECRUITING

Mayo Clinic Jacksonville - PPDS, Jacksonville

37007

RECRUITING

Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca, Salamanca

40447

RECRUITING

Local Institution - 403, Taichung

57010

RECRUITING

Georgios Papanikolaou General Hospital of Thessaloniki, Thessaloniki

66160

RECRUITING

University Of Kansas Medical Center, Kansas City

68198

RECRUITING

University of Nebraska - Fred and Pamela Buffet Center, Omaha

77003

RECRUITING

MD Anderson Cancer Center, Houston

85259

RECRUITING

Mayo Clinic - Arizona, Scottsdale

100229

RECRUITING

National Taiwan University Hospital, Taipei

55905-0001

RECRUITING

Mayo Clinic - Rochester, Rochester

WA 6000

COMPLETED

Local Institution - 503, Perth

NSW

WITHDRAWN

Local Institution - 502, Waratah

11 527

RECRUITING

"General Hospital of Athens Laiko", Athens

80-952

RECRUITING

Uniwersyteckie Centrum Kliniczne, Gdansk

30-727

RECRUITING

MCM Krakow - PRATIA - PPDS, Krakow

60-185

RECRUITING

Centrum Medyczne Pratia Poznan, Poznan

WITHDRAWN

Local Institution - 0706, Poznan

WITHDRAWN

Local Institution - UNK0706, Poznan

32-090

RECRUITING

SP ZOZ Szpital Uniwersytecki w Krakowie, Słomniki

02-781

RECRUITING

Local Institution - 602, Warsaw

50-367

COMPLETED

Local Institution - 604, Wroclaw

06351

COMPLETED

Local Institution - 300, Seoul

138-736

COMPLETED

Local Institution - 302, Seoul

08916

RECRUITING

Hospital Universitari Germans Trias i Pujol ICO Badalona, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Celgene

INDUSTRY